Register for alerts
If you have registered for alerts, you should use your registered email address as your username
Inhaled corticosteroids are the most effective medicine to treat persistent asthma. Inhaled corticosteroids are asthma controller medicines. Asthma symptoms happen less often when an inhaled corticosteroid is used every day. When used every day, these medicines make the breathing tubes less sensitive by blocking the inflammation that leads to asthma symptoms.
Using a controller medicine reduces the need for rescue medicines and lowers the chance of needing to go to the emergency room for an asthma attack.
Because the main problem in asthma is long-term inflammation in the lungs, corticosteroids are often used to treat asthma. Corticosteroids help to reduce and prevent the swelling and excess mucus in the airway caused by inflammation.
For most people with asthma, corticosteroids are the single most effective medicine because they break the inflammation cycle and reduce the likelihood of future asthma flare-ups.
Inhaled corticosteroids are not like anabolic steroids. Although they have a similar name, they are very different from the anabolic steroids that are abused by some athletes. Also, it is important to know that concerns about using oral corticosteroids do not apply because inhaled corticosteroids are not absorbed into the body to any large extent .
A small number of individuals experience some local side effects, such as a yeast infection (white spots) of the mouth, tongue or throat and occasional hoarseness. Side effects can be avoided by rinsing the mouth after each treatment and using a spacer with a metered dose inhaler .
LABA+ICS群と比較し、LAMA+LABA群の統合された主要評価項目の結果は以下の通りである：増悪、OR (95％CI ～、P = 、I 2 = 17％、低い質のエビデンス)；重篤な副作用、(95％CI ～、P = 、I 2 = 0％、中等度の質のエビデンス)；St. George's Respiratory Questionnaire (SGRQ)ベースラインからの変化、MD -(95％CI ～、P = 、I 2 = 71％、低い質のエビデンス)；トラフ一秒量ベースラインからの変化、MD (95％CI ～、P <、I 2 = 50%、中程度の質のエビデンス)。同様に二次評価項目の結果は以下の通りである：肺炎、OR (95％CI ～、P = 、I 2 = 0％、低い質のエビデンス)；全死亡、OR (95％CI ～、P = 、I 2 = 0％、低い質のエビデンス)、臨床的有意な最小変化量(4点)以上のSGRQベースラインからの改善、OR (95％CI ～、P = 、I 2 = 0％、中等度の質のエビデンス)。